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The majority of women requiring chemotherapy for gestational trophoblastic disease (GTN) are cured with their initial
chemotherapy treatment. However, a small percentage either become refractory to treatment, or relapse after the completion of
treatment. This study investigates the characteristics and outcome of these patients. Patients were identified from the Charing Cross
Hospital GTD database. The outcome of these patients with relapsed disease was compared to those with refractory disease.
Between 1980 and 2004, 1708 patients were treated with chemotherapy for GTN. Sixty (3.5%) patents relapsed following
completion of initial therapy. The overall 5-year survival for patients with relapsed GTN was 93% (95% CI 86–100%). The overall
survival for patients with low-risk and high-risk disease at presentation, who subsequently relapsed was 100% (n¼35), and 84%
(n¼25) (95% CI: 66–96%: Po0.05), respectively. Eleven patients were identified who failed to enter remission and had refractory
disease. These patients had a worse outcome compared to patients with relapsed disease (5-year survival 43% (95% CI:12–73%
Po0.01)). The outcome of patients with relapsed GTN is good. However, patients with primary chemo-refractory disease do poorly
and novel therapies are required for this group of patients.
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Gestational trophoblastic disease comprises a spectrum of
disorders ranging from the premalignant complete and partial
hydatidiform moles to the malignant invasive mole, choriocarci-
noma and rare placental site trophoblastic tumours (PSTT). The
latter three conditions are also collectively known as gestational
trophoblastic tumours or neoplasia (GTN). The majority of
patients with GTN are cured with chemotherapy. The intensity
of the initial chemotherapy for invasive mole and choriocarcinoma
is dependant on the risk factors at presentation, with patients
stratified into low- and high-risk prognostic groups (Ngan, 2004).
These two groups of patients are treated differently. The low-risk
patients receive single-agent therapy, most commonly with
methotrexate, whereas high-risk patients are treated with combi-
nation chemotherapy, using weekly combination chemotherapy,
comprising of etoposide, methotrexate, actinomycin alternating
with cyclophosphamide and vincristine (EMA-CO) at our institu-
tion (Bagshawe, 1976). The outcome of both the groups of patients
is good with 5-year survival of 100% for low-risk and 86% for
high-risk patients (Farhat et al, 1996; Bower et al, 1997). However,
a small minority of patients with GTN will relapse after the
completion of treatment.
Owing to the rarity of the disease and the small number of
patients relapsing after treatment, there are few publications
examining the management and outcome of this group. Addition-
ally, previous studies have combined relapsed patients with those
that have progressive disease on chemotherapy (refractory disease)
(Lurain and Nejad, 2005; Matsui et al, 2005). However, in other
curable cancers such as lymphoma and germ cell tumours, there is
evidence that the outcome for relapsed as opposed to primary
refractory disease is different (Proctor et al, 2001; McNeish et al,
2004). Here, we separately describe and compare the character-
istics, management and outcome of patients who relapse following
chemotherapy with those who have primary chemotherapy
refractory disease.
PATIENTS AND METHODS
The Charing Cross GTD database includes full clinical details of
women diagnosed with GTN. It was screened to identify women
who had primary refractory disease or relapsed after completion of
chemotherapy for GTN between 1980 and 2004.
Patients with relapsed disease
Relapse was defined as two elevated and increasing serum human
chorionic gonadotropin (hCG) levels, in the absence of a normal
pregnancy, after achieving complete serological remission with
chemotherapy. Complete remission was defined as a minimum of
6 weeks of normal hCG values on chemotherapy. At this point,
chemotherapy was stopped and patients entered the post-
treatment screening programme. The post-treatment screening
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sprogramme involves once weekly blood tests for 6 weeks, then two
weekly blood and urine samples up to 6 months, followed by urine
samples two weekly for the rest of the first year. From there, urine
hCG is measured at increasing intervals up to 5 years. At this point
urine is requested every 6 months for life.
Patients with refractory disease to EMA/CO therapy
This group includes high-risk GTN patients whose hCG had
increased, or failed to decrease (plateau) on EMA/CO chemo-
therapy. Human chorionic gonadotropin levels were assessed twice
weekly on treatment according to the protocol. As hCG can
initially rise and/or take 2–4 weeks before falling following
commencement of chemotherapy, patients were given at least 3
weeks of EMA/CO before a diagnosis of refractory disease could be
made.
Refractory disease was defined as:
1. Two or more abnormal and increasing plasma hCG levels,
despite receiving standard EMA/CO chemotherapy for at least
3 weeks.
2. Three or more consecutive hCG values that had failed to fall
more than 5% below the preceding hCG level. These patients
were considered to have a plateau in their hCG.
Patients with refractory disease went on to receive platinum-
based chemotherapy (see later for treatment details). Nine patients
with high-risk disease were excluded from this study because they
died early from GTN, before a fall in the hCG could be attributed to
chemotherapy resistance.
Other exclusion criteria
Patients with PSTT were excluded from this analysis because
the treatment and outcomes for these patients are different
(Papadopoulos et al, 2002)
Details at initial diagnosis of GTN
At initial diagnosis, patients were staged according to the national
and internationally accepted criteria for GTN, and then stratified
into low- or high-risk groups and treated accordingly (Bagshawe,
1976; Kohorn, 2001). Patients were treated in a uniform manner
using the standard well-established treatment protocols of
methotrexate/folinic acid and EMA-CO. Women with in the low-
risk group received intramuscular methotrexate with folinic acid.
In the event of resistance to methotrexate, characterised by a rise
or plateau in the serum hCG, treatment was switched to
actinomycin D or the EMA-CO high-risk treatment regimen,
depending on the hCG level as described previously (McNeish
et al, 2002). The majority of patients with high-risk disease were
commenced EMA/CO. However, in the presence of brain or liver
metastasis different regimens were used (EMA/CNS (high doses of
methotrexate) or EP/EMA (EP¼etoposide and cisplatin), respec-
tively) (Rustin et al, 1989; Bower et al, 1997; Newlands et al, 2000).
Investigations and treatment at diagnosis of relapse of
GTN
Patients who relapsed underwent restaging, which included a
pelvic Doppler US, CT body and CT or MRI brain. The treatment
for patients who relapsed after methotrexate or actinomycin for
(low-risk disease) was either surgery alone (if the relapse was
isolated) or EMA/CO with or without surgery. For those relapsing
after EMA/CO (high-risk disease) treatment was either surgery
and/or EP/EMA. Relapsed patients were stratified into relapse after
initial high- and low-risk treatment for comparative purposes.
Investigations and treatment at diagnosis of refractory
disease
The details and characteristics of these patients were noted at the
time of development of refractory disease. Patients went on to
receive platinum-based chemotherapy usually EP/EMA (Newlands
et al, 2000).
Statistical methods
Survival was calculated from the day of diagnosis until death or the
date of last follow-up. Overall survival duration curves were
plotted according to the method of Kaplan and Meier. Comparison
of variables between groups was by w
2 test for nominal variables,
and Mann–Whitney U-test for non-parametric variables, log-rank
tests were used to compare overall survival over time and all
P-values presented are two-sided. Univariate analysis was per-
formed on the cohort with relapsed disease.
RESULTS
Patients characteristics (Table 1 and Figure 1)
From a database of 1708-treated GTN patients, 60 (3.5%) relapsed
after chemotherapy, 35 of 1397 (2%) low-risk patients relapsed
compared to 25 of 311 (8%) high-risk patients. Eleven patients
fulfilled the criteria for disease refractory to EMA/CO
chemotherapy.
Details of relapsed patients at initial presentation of GTN
(Table 1)
The characteristics of the 60 patients who relapsed are given in
Table 1. At initial presentation, 35 (58%) patients were in the low-
risk prognostic group and received single-agent methotrexate,
eight of these patients became resistant to methotrexate and
changed to more intensive chemotherapy two with EMA/CO and
six with actinomycin (McNeish et al, 2000).
The remaining 25 (42%) patients initially presented with high-
risk disease and were treated accordingly: 17 received EMA/CO
chemotherapy, six patients received platinum containing regimens
or other regimens including cisplatin etoposide (n¼1), cisplatin
etoposide and vincristine (n¼1). These other regimens were used
because of the presence of extra-pulmonary metastasis, intolerance
of methotrexate or treatment predating the routine introduction of
EMA/CO chemotherapy.
Details of patients at relapse (Table 2)
The characteristics of the patients at the time of relapse are shown
in Table 2. The majority of relapses (73%) occurred within 1 year
of completing initial chemotherapy and only one patient relapsed
after more than 5 years of follow-up (Table 3). Human chorionic
gonadotropin screening of either blood or urine samples identified
47 (78%) of these relapses. Thirteen represented with symptoms
(predominantly amenorrhoea), including two patients who did not
comply with screening and presented with symptomatic relapse.
Treatment at relapse of GTN (Table 4)
Treatment at the time of relapse depended on a number of factors.
The most important of which were previous treatment at initial
presentation (high- vs low-risk prognostic group) and site of
disease.
Most women initially treated with methotrexate for low-risk
disease received EMA/CO at relapse, although other regimens were
used in five patients due to intolerance of EMA/CO (Table 4).
Relapse after initial high-risk chemotherapy was treated with
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splatinum-based chemotherapy in the majority of patients, most
frequently the EP/EMA regimen (15 out of 25). EMA/CO was
reused successfully at relapse in three patients with a long
treatment-free interval (41 year). Patients with brain metastasis
received EMA/CO with high-dose methotrexate (Rustin et al,
1989).
Surgery was performed, in conjunction with chemotherapy, in
15 women with easily resectable metastasis isolated from one
organ. Two patients with low-risk disease and isolated uterine
relapse underwent a hysterectomy without chemotherapy owing to
patient preference, one of these patients relapsed and required
chemotherapy and was cured.
There were no treatment-related deaths in this group of patients
with relapsed GTN.
Outcome of patients with relapsed GTN (Table 4)
After a median follow-up of 10.8 years (range 1.7–24.5) after
relapse, there have been five deaths among the 60 patients with
relapsed disease, all owing to progressive chemotherapy-resistant
GTN. These patients received third-line therapy (high-dose
treatment in four (McNeish et al, 2004)). Although markers
temporarily normalised in two of these patients, none went into a
sustained complete remission. Ultimately, all patients progressed
and died of progression of disease in multiple sites. All five deaths
occurred in patients falling into the initial high-risk prognostic
group; none of these patients who died achieved a complete
remission with second-line platinum-based chemotherapy. All of
these five patients progressed on third-line therapy. Indeed all of
the women who went into complete remission after second-line
treatment are alive, whereas all patients who progressed on
second-line treatment have died of GTN. The 5-year overall
survival was 93% (95% CI: 68–100%), this dropped to 84%
(95%CI: 68–99%) for patient with high-risk disease. None of the
patients initially within the low-risk prognostic group died.
Overall nine patients have relapsed for a second time; three from
the initial low-risk disease group and six from the initial high-risk
group. The median time interval between first and second relapse
was 0.8 years (range 0.3–4.6). All of these patients went into
complete remission with third-line treatment and are alive with
a median follow-up of 13.0 years (range 3.0–22.3). This third-line
treatment included surgery (n¼1), chemotherapy (n¼5) and
chemotherapy and surgery (n¼3). The chemotherapy regimens
used included high-dose therapy (n¼2) and, EP/EMA (n¼5),
EMA/CO (n¼1). Indeed two of these patients have relapsed for a
third time and are in remission with fourth-line chemotherapy,
with 4.5 and 7.3 years of follow-up.
Prognostic factors for patients with relapsed disease
(Table 5)
A number of clinical variables were found to be of prognostic
importance using univariate analysis. These included the presence
of metastasis at relapse, where the 5-year overall survival was 79%
(95%CI: 61–97) for patients with metastasis and 97% (95%CI: 87–
100) for patients without metastasis. Other significant factors
included a slow hCG-doubling time at relapse, high-risk disease at
presentation and term pregnancies. Multivariate analysis was
precluded due to the small sample size in conjunction with the
small number of events.
Patients with refractory disease (Table 1 and Figure 2)
Eleven patients progressed on EMA/CO chemotherapy and fulfilled
the criteria for refractory disease. Seven of these patients had
consecutive rising hCG levels on chemotherapy, whereas the other
Relapse 35 (2%)
5-year OS: 100%
Other* 1362 (98%) 
Relapse 25 (8%)
5-year OS: 93%
Refractory 11 (4%)
5-year OS: 43% 
Other* 273 (88%) 
Low-risk disease  n=1397 (87%) 
High-risk disease  n =309 (23%) 
Figure 1 Origin of patients with relapsed or refractory GTN.
Table 1 Characteristics at initial presentation of disease for patients who developed relapsed GTN (n¼60)
Characteristic
All relapsed patients (high- and
low- risk at initial diagnosis)
Patients with high-risk disease at
initial diagnosis who relapse Refractory disease
Number 60 25 11
Median prognostic score (WHO) at diagnosis 7 (range 2–23) 9 (range 8–23) 16 (range 8–26)
Median prognostic score (FIGO) 4 (range 1–12) 7 (range 5–12) 10 (range 6–18)
Antecedent pregnancy Term 19
Abortion 7
Mole 34
Term 17
Abortion 5
Mole 3
Term 7
Abortion 1
Mole 3
Median hCG before initial treatment 21000 (range 31–814000) 66000 (range 350–814000) 380000 (range 79000–1100000)
Duration between causal pregnancy and initial
treatment
0.4 years (range 0.1–7.3 years) 1.1 years (range 0.1–7.3 years) 3.2 years (range 0.1–15)
Uterine size 0–3cm–15
3–5cm–39
45cm–6
0–3cm–7
3–5cm–16
45cm–2
0–3cm5
3–5cm–4
45cm–2
Site of metastasis None 40
Lung only 16
Other sites
a 4
None 12
Lung only 9
Other sites
a 4
None 0
Lung only 7
Other sites
b 4
Initial treatment regimens Methotrexate 35
EMA/CO 18
Platinum-based 7
EMA/CO 17
Platinum-based 7
EMA/CO 11
GTN¼gestational trophoblastic neoplasia; WHO¼World Health Organization.
aWith or without lung metastasis (includes liver (2), brain (1) and liver and brain(1).
bLiver, 2;
brain, 2.
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sfour had a plateau in their hCG. All of these patients received
platinum-based chemotherapy (EP/EMA 8, EP 3). Six of these
patients have died with a median overall survival of 1.2 years. All
six patients died of chemoresistant GTN, four of these patients
subsequently received high-dose therapy. These patients have a
poor prognosis compared to those with relapsed disease after
high-risk treatment (5-year survival 43% (95% CI: 68–99%) vs
84% (95%CI: 12–73% (P¼0.003)). It is noteworthy that these
patients had poor prognostic at diagnosis features compared to the
high-risk relapse patients (Table 1).
DISCUSSION
This is the largest reported series of GTN patients with either
relapsed disease after chemotherapy or refractory disease. The
main findings are that the relapse rate following chemotherapy is
low (3.5%) and the majority of these patients can be cured with
further treatment (490%). However, patients with disease which
is refractory to high-risk treatment have a significantly less good
outcome.
None of the women who relapsed after low-risk disease died,
which is reassuring for these patients. Additionally, extrapolating
from previously published data, the 5-year survival of patients with
relapse after high-risk disease is similar to that for high-risk
patients at initial presentation (84% (95% CI: 68–99%) vs 86%
(95%CI: 82–91%), respectively) (Bower et al, 1997; Dobson et al,
2000). All of the relapsed patients who died failed to go into
complete remission with second-line chemotherapy at relapse.
Therefore, obtaining a complete serological remission with
second-line chemotherapy is crucial for these patients.
This work also shows the outlook for patients with chemother-
apy refractory disease is less good. These findings are consistent
with data from other tumour types such as ovary and testis, which
demonstrate a difference in outcome regarding patients with
refractory and relapsed disease (Thigpen et al, 1993; McCaffrey
et al, 1997; Herzog, 2002).
Owing to the lack of published data, there is no specific scoring/
prognostic system for relapsed or refractory patients. The WHO
and FIGO scoring systems are used to separate women into
high- and low-risk disease at initial presentation. Although these
scoring systems do include prognostic scores (points) for previous
treatment (up to six points), the scoring system has not been
widely evaluated or validated for these rare patients. Although
numbers are small, the data presented here do highlight a number
Table 2 Patients characteristics at time of relapse or refractory disease
Patients with relapsed disease Patients with refractory disease
Number 60 11
Median time to relapse or refractory disease (months) 4 months (range 0.25–37 months) 3 months (range 0.25–6.75)
Median hCG at relapse/refractory disease 309 (range 25–105000) 1244 (range 14–255000)
Rate of hCG rise (median doubling time in days) 9 days (range 3–28) days) NA
Median time between diagnosis of relapse and starting treatment (months) 0.4 months (range 0–3) NA
Symptoms/method of diagnosis of relapse hCG Screening 47
PV bleeding 2
Amenorrhoea 7
Other
a 4
Screening 11
Site of disease at relapse hCG relapse12
Mass in uterus only 29
Lung 12
Lung and uterus 3
Pelvis 1 other and uterus 3
b
Unknown 1
NA
HCG¼human chorionic gonadotropin; NA¼not available.
aRespiratory symptoms, haemoptysis and re-entry to screening programme.
bIncludes liver (1), liver and brain(1),
pelvis (2).
Table 3 Time to relapse after chemotherapy
Time to relapse Number (%) Cumulative (%)
0–3 months 31 (51.6) 51.6
3–6 months 10 (16.6) 68.2
6–12 months 3 (5) 73.2
12–24 months 7 (11.7) 84.9
1–5 years 8 (13.5) 98.4
45 years 1 (1.6) 100
Table 4 Management and outcome of relapsed disease
Low risk at initial presentation patients n¼35
Hysterectomy only 2
Hysterectomy and chemotherapy EMA/CO 3
EP 1
Chemotherapy only EMA/CO 25
CO/EP 1
EP 1
EP/EMA 2
5-year survival 100%
High risk at initial presentation patients n¼25
Thoracotomy and chemotherapy EP/EMA 2
POMB ACE 1
EMA/CO 1
Hysterectomy and chemotherapy EP/EMA 3
EMA/CO 1
Cis/taxol 1
Chemotherapy only EMA/CNS 1
EMA/CO 3
EP/EMA 10
Cisplatin vincristine 1
Cis/taxol 1
5-year survival 84% (95% CI: 68–99%)
EMA/CO – weekly combination chemotherapy, comprising of etoposide(dose),
methotrexate, actinomycin alternating with cyclophosphamide and vincristine (Bower
et al, 1997). POMBACE – cisplatin, vincristine, methotrexate, bleomycin alternating
with actinomycin D, cyclophosphamide and etoposide (Newlands et al, 1983).
EP/EMA – etoposide, cisplatin/etoposide, methotrexate and actinomycin D (New-
lands et al, 2000). EMA/CNS – etoposide, methotrexate and actinomycin alternating
weekly with vincristine and cyclophosphamide. The dose of methotrexate was
increased to 1gm
 2. Cis/taxol – cisplatin etoposide and paclitaxel (Osborne et al,
2004) EP cisplatin etoposide (IV day 1–5).
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sof factors which were of poor prognostic importance in univariate
analysis, these include metastatic disease at relapse, previous high-
risk treatment, previous nonpulmonary metastases, nonmolar
pregnancies and a slow hCG-doubling time (410 days). These
factors may give us a better insight into predicting the outcome of
these patients. For example, none of the women with two or less of
these factors have died. Unfortunately, in view of the rarity of the
disease and small number of deaths in this cohort, it is not possible
to construct and validate a prognostic scoring system.
The observation that patients with a slow hCG-doubling time at
relapse appear to have a worse outcome compared to those with a
rapid doubling time is interesting. The reasons for this are unclear,
but a slow doubling time may be a mark of a slow growing,
chemotherapy-resistant tumour or a tumour that no longer
secretes hCG appropriately due to mutation or differentiation as
has been described with other cancers (Fossa et al, 1992). However,
the time between initial diagnosis and relapse was not significant
in univariate analysis. This may in part be due to the small
numbers because of the rarity of the disease.
Currently, clinicians at the Charing Cross Hospital are treating
patients with relapse after methotrexate for low-risk disease with
EMA/CO, which seems appropriate as the overall survival is 100%
in this group. EMA/CO is first-line high-risk treatment at the
Charing Cross; however, other regimens such as MEA (metho-
trexate, etoposide and actinomycin) (Dobson et al, 2000) are used
at other centres. These appear to have similar relapse and overall
survival rates, although direct comparison as part of a study has
not been performed. The majority of patients who relapsed after
initial high-risk treatment in this series received EP/EMA, which
has previously been shown to be a potent regimen in GTN
(Newlands et al, 2000). Three high-risk relapse patients were
retreated with EMA/CO because of a long interval between
treatments (41 year). None of these three have relapsed, which
gives us some insight into the mechanism of chemotherapy
resistance in this tumour type. Paclitaxel in combination with
cisplatin and etoposide is a promising regimen in chemotherapy-
resistant GTN and used successfully twice in this series (Osborne
et al, 2004).
The role of surgery in the management of relapse GTN is
unknown. It is theoretically curative without the need for further
chemotherapy, if complete excision is achieved and postopera-
tively the hCG falls with an appropriate half-life of 1–2 days.
However, this study shows that surgery alone may be inadequate,
and so the decision not to give further chemotherapy should be
carefully considered. If the disease is isolated in the uterus,
hysterectomy plus chemotherapy is a safe option and may reduce
the duration of chemotherapy treatment (Soper, 2003). However,
the majority of women maintain their fertility after chemotherapy
and therefore, if a patient wishes to have children, chemotherapy
alone is preferable (Bower et al, 1997).
Owing to the sensitive and specific nature of hCG in GTN,
screening has been offered to relapsed patients after treatment.
Table 5 Univariate analysis for patients with relapsed disease
GTN-related deaths
Yes No P-value
Median age at relapse (years) 32 29 0.26
Median hCG at presentation 15000 28000 0.14
Median interval between causal pregnancy and first chemotherapy 1.1 years 0.5 years 0.57
Maximum hCG at relapse (medium) 350 121 0.41
HCG doubling time at relapse (days) 15 7 0.01*
Lung metastasis at presentation No 2 42 0.11
Yes 3 13
Nonpulmonary metastasis at presentation No 3 52 0.05*
Yes 2 3
Treatment at initial presentation High risk 5 20 0.01*
Low risk 0 35
Interval between chemotherapy and relapse 0–3 months 4 30 0.19
43 months 1 25
Metastasis identified at relapse No 1 39 0.03*
Yes 4 16
Uterine mass identified at relapse No 3 24 0.65
Yes 2 31
Nonpulmonary metastasis at relapse No 4 52 0.30
Yes 1 3
Causal pregnancy Mole 0 29 0.02*
Term 5 26
0
0.8
0.6
0.4
0.2
1
0 5 10 15 20 25
Years
Refractory n=11
Relapsed n=25
P=0.0031
5-year OS 
Relapsed=84% (95% CI: 68–99) 
Refractory=43% (95% CI: 12–73) 
Figure 2 Outcome of patients who relapsed after high-risk treatment vs
refractory (progression on initial high-risk chemotherapy).
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sThe data in this study show that most patients relapse within the
first 6 months and the majority are detected by the screening
programme. This finding confirms the benefit of the testing
schedule for these women following chemotherapy. It is interesting
that 15% patients relapsed after 2 years, which underlines the need
to continue monitoring these women.
This study also investigated patients with disease refractory to
high-risk therapy. These patients have poor outcome compared to
those with relapsed disease and once again underlines the
importance of obtaining a normal hCG with treatment for GTN.
There are two other publications in this area, both of
which combined patients with resistant and relapsed disease
together (Lurain and Nejad, 2005, Matsui et al, 2005). In the study
by Matsui et al, only six patients with low-risk disease relapsed,
and therefore, it is difficult to draw too many conclusions from
this, although none have died, which is consistent with our data.
The other study focused on 26 patients with high-risk disease and
did not distinguish between refractory disease and relapse. As we
have shown in this study, these two groups of patients have
differing outcomes, making the interpretation of their results
complex.
Although all patients in this series were initially diagnosed with
histologically confirmed gestational trophoblastic disease, it is
possible that some of the high-risk patients who were refractory or
relapsed may in fact have had non-gestational hCG producing
tumours that masquerade as GTN (Fisher and Newlands, 1998). In
a number of isolated cases, we have performed genetic analysis
to confirm the non-gestational genetic origin of the tumour.
However, it is not possible to perform testing in all cases.
Therefore, it is conceivable that there will be a small proportion of
non-gestational tumours in this series. An additional shortcoming
of this work is that none of the relapsed tumours were genetically
tested to confirm that the disease was truly relapse, rather than a
second unrelated tumour. However, there are a number of factors,
which strongly support the theory that these patients have
relapsed. These include the short period between completing
chemotherapy and relapse of disease (median 4 months).
Additionally, the patients with relapsed disease presented in a
different manner to those at initial presentation, with a higher
proportion with metastatic disease, comparatively low hCGs and
low burden of disease in the uterous. Indeed no abnormality was
noted in the uterous in 41% of patients at relapse. Despite this, it is
not possible to completely rule out the possibility that some of
these tumours were due to a second primary tumour without
genetic testing.
In summary, the outcome of women with relapsed GTN is good,
especially those initially treated with low-risk disease.
The outcome for patients with refractory disease is less favourable.
Monitoring patients after relapse is recommended for at least
5 years
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